RESUMO
During the COVID-19 vaccination rollout from March 2021- December 2022, the Centers for Disease Control and Prevention funded 110 primary and 1051 subrecipient partners at the national, state, local, and community-based level to improve COVID-19 vaccination access, confidence, demand, delivery, and equity in the United States. The partners implemented evidence-based strategies among racial and ethnic minority populations, rural populations, older adults, people with disabilities, people with chronic illness, people experiencing homelessness, and other groups disproportionately impacted by COVID-19. CDC also expanded existing partnerships with healthcare professional societies and other core public health partners, as well as developed innovative partnerships with organizations new to vaccination, including museums and libraries. Partners brought COVID-19 vaccine education into farm fields, local fairs, churches, community centers, barber and beauty shops, and, when possible, partnered with local healthcare providers to administer COVID-19 vaccines. Inclusive, hyper-localized outreach through partnerships with community-based organizations, faith-based organizations, vaccination providers, and local health departments was critical to increasing COVID-19 vaccine access and building a broad network of trusted messengers that promoted vaccine confidence. Data from monthly and quarterly REDCap reports and monthly partner calls showed that through these partnerships, more than 295,000 community-level spokespersons were trained as trusted messengers and more than 2.1 million COVID-19 vaccinations were administered at new or existing vaccination sites. More than 535,035 healthcare personnel were reached through outreach strategies. Quality improvement interventions were implemented in healthcare systems, long-term care settings, and community health centers resulting in changes to the clinical workflow to incorporate COVID-19 vaccine assessments, recommendations, and administration or referrals into routine office visits. Funded partners' activities improved COVID-19 vaccine access and addressed community concerns among racial and ethnic minority groups, as well as among people with barriers to vaccination due to chronic illness or disability, older age, lower income, or other factors.
RESUMO
The laparoscopic approach to appendectomy for acute appendicitis is becoming increasingly favored among surgeons. Endoscopic stapling remains a common approach for division of the appendix and mesoappendix, but staple line bleeding along the mesentery is commonly observed, occasionally demanding surgical control for complete hemostasis. Bioabsorbable seamguard was used as an adjunct to endoscopic stapling of the mesoappendix in 33 consecutive adult patients during laparoscopic appendectomy for acute appendicitis, with complete immediate staple line hemostasis observed by the operative surgeon in all cases. There were no intraoperative complications and no late infectious intra-abdominal complications. There were no postoperative bleeding complications. Bioabsorbable seamguard is a safe and effective adjunct to endoscopic mesoappendiceal stapling which prevents intraoperative and postoperative staple line bleeding.
